Batp.Bo
Bharat Antibiotics Limited (BATP.BO) is a pharmaceutical company engaged in the development, manufacturing, and sale of antibiotics and other pharmaceutical products in India.
Business. Bharat Antibiotics Limited (BATP.BO) is a pharmaceutical company engaged in the development, manufacturing, and sale of antibiotics and other pharmaceutical products in India.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
Bharat Antibiotics Limited (BATP.BO) is a pharmaceutical company engaged in the development, manufacturing, and sale of antibiotics and other pharmaceutical products in India.
The company's capital structure is characterized by a debt-to-equity ratio of 0.54, indicating a moderate level of leverage. However, its liquidity position is rated as medium, with a current ratio of 1.62, suggesting that the company has sufficient short-term assets to cover its short-term liabilities, but not with a large margin of safety. The company's free cash flow is negative at -379.64 million INR, and its operating cash flow is also negative at -272.54 million INR, indicating that the company is not generating positive cash from its operations.
In terms of profitability, the company is underperforming, with a return on equity of -3.82% and a return on assets of -1.95%. These figures are significantly below the industry norms for pharmaceutical companies, which typically exhibit positive returns on equity and assets. The company's operating income is negative at -315.72 million INR, and its net income is also negative at -126.26 million INR, indicating that the company is currently unprofitable.
The company's revenue is concentrated in a single business segment, as disclosed in its financial statements, with no material geographic diversification reported. This lack of diversification increases the company's exposure to market-specific risks, particularly in the Indian pharmaceutical market.
The company's growth trajectory is uncertain, with no specific revenue growth projections provided in the available data. The negative operating and net income figures suggest that the company is not currently on a path of sustainable growth. The company's capital expenditures are also negative, indicating a reduction in investment in long-term assets.
The company faces several risk factors, including its negative net cash position after subtracting total debt, which is a key flag in the risk assessment. The company's liquidity risk is rated as medium, and its credit risk is not explicitly stated but is implied to be moderate given its leverage and cash flow position. The dilution risk is rated as low, with no significant dilution expected in the near term.
Recent events, as disclosed in the company's financial filings, include a continued decline in profitability and cash flow generation. The company has not disclosed any major strategic initiatives or new product launches that could potentially reverse its current financial trajectory.
- BATP.BO is a pharmaceutical company with a negative return on equity and assets, indicating poor profitability.
- The company's liquidity position is moderate, with a current ratio of 1.62, but it is not generating positive cash from operations.
- The company's capital structure is moderately leveraged, with a debt-to-equity ratio of 0.54.
- The company's growth trajectory is uncertain, with no clear path to profitability or revenue growth.
- The company faces liquidity and credit risks due to its negative cash flow and net income.
- The company's risk of dilution is low, but its overall financial health is a concern.
Bull / Bear case
analysis pipelineIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Capex To Revenuecapital_expenditure / revenue
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
- BATP.BO Market data — financials · 2026-05-27